Replay of the Press Conference on ColdZyme, March 5, 2025
14 March 2025
On March 5, Enzymatica hosted a digital press briefing to discuss recent findings published in The Journal of Physiology regarding ColdZyme. Professors Glen Davison and Doris Wilflingseder, the principal investigators of the studies, presented their research outcomes and addressed questions from attendees.
The studies demonstrated that ColdZyme effectively reduces viral load and shortens the duration of upper respiratory tract infections. Participants using ColdZyme experienced milder symptoms and fewer sick days compared to those who did not use the product.
Following the research presentations, Enzymatica's CEO, Claus Egstrand, and Chairman, Bengt Baron, provided a corporate update, highlighting the implications of these findings for the company's strategic direction and market expansion plans.
For those interested in viewing the press conference, a replay is available at the following link: